Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announces the addition of Kimberly Blackwell, M.D., as Chief Medical Officer and Kenneth Carson, M.D., as Vice President of Clinical Solutions.
“Our platform is designed to help clinicians make real-time, data-driven decisions in an effort to insure that every patient is on their own optimal therapeutic path,” said Eric Lefkofsky, Founder and CEO of Tempus. “As practicing oncologists, with unique and diverse backgrounds, Kim and Ken not only bring world-class expertise to our team, but also have the experience and insight we need as we seek to develop and deploy technologies that improve patient outcomes in cancer, and other diseases.”
Dr. Blackwell joins Tempus from Eli Lilly, where she was Vice President of Early Phase Oncology and Immuno-oncology. Prior to that, she was a Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University, where she directed the Women’s Cancer Program, Strategic Collaborations, and the Precision Medicine Initiative for the Duke Cancer Institute. Dr. Blackwell received her M.D. from Mayo Clinic Medical School, followed by training in internal medicine and hematology-oncology at Duke University.
“Over the years, I’ve played several different roles in bringing new therapies to patients facing cancer— having worked as a clinical trialist, practicing oncologist, and most recently, a pharmaceutical company researcher,” said Dr. Blackwell. “By joining Tempus, I want to continue to contribute to improving access and developing highly effective drugs to patients facing cancer. Tempus provides a unique opportunity for me to leverage my prior clinical and research experience to impact both current and future cancer patients at scale, given the breadth of scope of Tempus’ platform.
Dr. Carson joins Tempus from Flatiron Health, where he was a Senior Medical Director. Prior to Flatiron Health, Dr. Carson established a clinical practice in the Department of Internal Medicine at Washington University School of Medicine in St. Louis. He later became chief of the hematology and oncology section at the St. Louis Veterans Affairs healthcare system. Dr. Carson received his M.D. from the University of Southern California’s Keck School of Medicine, followed by residency training in internal medicine at Duke University.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitate discovery, development and delivery of optimized therapeutic options for patients through distinctive solution sets. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.